

General information about company		
Scrip code*	539872	
NSE Symbol*	BAJAJHCARE	
MSEI Symbol*	NOTLISTED	
ISIN*	INE411U01027	
Name of company	BAJAJ HEALTHCARE LIMITED	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Date of board meeting when results were approved	26-05-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	20-05-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Fourth quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Single segment	
Description of single segment	Pharmaceuticals	
Start date and time of board meeting	26-05-2025 16:10	
End date and time of board meeting	26-05-2025 16:52	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether the company has any related party?	Yes	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes	
Latest Date on which RPT policy is updated	11-02-2025	
Indicate Company website link for updated RPT policy of the Company	https://www.bajajhealth.com/policies/	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	During the period ended 31.03.2025, there is no default.

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-01-2025	01-04-2024	
Date of end of reporting period		31-03-2025	31-03-2025	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	15447.25	54260.24	
	Other income	1357.16	1940.44	
	Total income	16804.41	56200.68	
2	Expenses			
(a)	Cost of materials consumed	10049.09	30710.9	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-652.23	-2066.37	
(d)	Employee benefit expense	1570.6	5705.83	
(e)	Finance costs	607.58	2790.44	
(f)	Depreciation, depletion and amortisation expense	753.1	2791.78	
(g)	Other Expenses			
1	Other Expenses	3304.07	11667.33	
	Total other expenses	3304.07	11667.33	
	Total expenses	15632.21	51599.91	
3	Total profit before exceptional items and tax	1172.2	4600.77	
4	Exceptional items	0	0	
5	Total profit before tax	1172.2	4600.77	
6	Tax expense			
7	Current tax	0	0	
8	Deferred tax	12.9	307.89	
9	Total tax expenses	12.9	307.89	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	1159.3	4292.88	
12	Profit (loss) from discontinued operations before tax	-88.03	-401.11	
13	Tax expense of discontinued operations	-46.51	-57.78	
14	Net profit (loss) from discontinued operation after tax	-41.52	-343.33	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	1117.78	3949.55	
17	Other comprehensive income net of taxes	345.17	137.01	
18	Total Comprehensive Income for the period	1462.95	4086.56	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			

	Paid-up equity share capital	1579.16	1579.16	
	Face value of equity share capital	5	5	
22	Reserves excluding revaluation reserve		0	
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	3.67	14.45	
	Diluted earnings (loss) per share from continuing operations	3.59	14.26	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	-0.13	-1.16	
	Diluted earnings (loss) per share from discontinued operations	-0.13	-1.14	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	3.54	13.29	
	Diluted earnings (loss) per share from continuing and discontinued operations	3.46	13.12	
24	Debt equity ratio	0.48	0.48	Textual Information(1)
25	Debt service coverage ratio	0.44	0.44	Textual Information(2)
26	Interest service coverage ratio	3.65	3.65	Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block																																	
Textual Information(4)	<p>3. The above audited financial results for the Year Ended 31 March 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards Ind AS,as prescribed under Section 133 of the Companies Act 2013 Act read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing obligations and disclosure requirements Regulations,2015 as amended.</p> <p>4. The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. 1. The above Financial Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 26 May 2025.</p> <p>2. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.</p> <p>5. In the previous financial year ended 31 March 2024, the Board of Directors had approved to sale or disposal of undertaking or units on going concern basis, situated at plot no. N92, L 9 3 , T30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D 2 CH 42 and D 2 CH 43 Dahej industrial area, GIDC, Bharuch, Gujarat which were acquired under SARFAESI ACT, 2022 from Saraswat Bank and plot no. E 62 and E 63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale or disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations. The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale, the assets have been recorded at their fair value on the date these assets has been classified as held for sale. Out of these, one unit situated at plot no. N92 was sold during the Quarter ended 31 March 2024. The total value of assets classified as held for sale represents lower of carrying value or fair value.</p> <p>The financial information from discontinued operations:</p> <table><tr><td>Particulars</td><td>Quarter Ended</td><td>Year Ended</td></tr><tr><td></td><td>31 March 2025</td><td>31 Dec 2024</td></tr><tr><td>31 March 2025</td><td>31 Dec 2024</td><td>31 March 2024</td></tr><tr><td>Total Income A</td><td>37.81</td><td>65.40</td></tr><tr><td>Total Expenses B</td><td>50.22</td><td>183.13</td></tr><tr><td>Loss before Tax from Discontinued Operations</td><td>88.03</td><td>117.73</td></tr><tr><td>Tax Expense Credit from Discontinued Operations D</td><td>46.51</td><td>206.71</td></tr><tr><td>Loss after Tax from Discontinued Operations</td><td>41.52</td><td>324.44</td></tr></table> <p>6. The Board of Directors the Company in their meeting held on 10 July 2024 and the shareholders of the company in ExtraOrdinary General Meeting EGM held on Wednesday, 07 August, 2024 through Video Conferencing VC or Other Audio Visual Means OAVM approved, the issue of 40,44,852 Equity Shares at Rs 338 per share to Person s belonging to non promoter category on preferential basis and the issue of convertible equity warrants 20,79,409 at Rs. 338 to Person s belonging to promoter category as well as non promoter category on preferential basis. The object of the issue is to repayment of term loan, investment in capital expenditure and general corporate purpose. The Company has also obtained the in principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024, post approval from Board, the Company has allotted 39,84,852 no. of equity shares and has also filed the relevant form with Registrar of Companies. The uncalled amount of share warrants as at 31 March 2025 is Rs. 5,271.30 lakhs.</p> <p>7. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities.</p> <table><tr><td>Particulars</td><td>Rs. in Lakhs</td></tr><tr><td>Repayment and prepayment of secured or unsecured loans from bank and NBFC</td><td>15,000.00</td></tr><tr><td>General corporate purpose</td><td>225.90</td></tr><tr><td>Total</td><td>15,225.90</td></tr></table> <p>8. During the previous year, the Company had written off inventories pertaining to certain covid portfolio products owing to continued lower demand, on a conservative basis.</p> <p>9. Subsequent to the year ended 31 March 2025, the Company acquired Genrx Pharmaceuticals Private Limited which was under liquidation on a going concern basis.</p> <p>10. The Board of Directors have recommended a Final dividend of 20% i.e. Rs. 1.00 Only per equity share on the face value of Rs. 5 each for the financial year ended 31 March 2025, subject to approval of shareholders in the ensuing Annual General Meeting.</p> <p>11. Previous year or period figures have been regrouped to make them comparable with the current year or period figures, which are not material.</p>	Particulars	Quarter Ended	Year Ended		31 March 2025	31 Dec 2024	31 March 2025	31 Dec 2024	31 March 2024	Total Income A	37.81	65.40	Total Expenses B	50.22	183.13	Loss before Tax from Discontinued Operations	88.03	117.73	Tax Expense Credit from Discontinued Operations D	46.51	206.71	Loss after Tax from Discontinued Operations	41.52	324.44	Particulars	Rs. in Lakhs	Repayment and prepayment of secured or unsecured loans from bank and NBFC	15,000.00	General corporate purpose	225.90	Total	15,225.90
Particulars	Quarter Ended	Year Ended																															
	31 March 2025	31 Dec 2024																															
31 March 2025	31 Dec 2024	31 March 2024																															
Total Income A	37.81	65.40																															
Total Expenses B	50.22	183.13																															
Loss before Tax from Discontinued Operations	88.03	117.73																															
Tax Expense Credit from Discontinued Operations D	46.51	206.71																															
Loss after Tax from Discontinued Operations	41.52	324.44																															
Particulars	Rs. in Lakhs																																
Repayment and prepayment of secured or unsecured loans from bank and NBFC	15,000.00																																
General corporate purpose	225.90																																
Total	15,225.90																																

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	23655.94
	Capital work-in-progress	344.85
	Investment property	0
	Goodwill	0
	Other intangible assets	188.87
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	0.33
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	560.85
	Total non-current financial assets	561.18
	Deferred tax assets (net)	1889.52
	Other non-current assets	572.98
	Total non-current assets	27213.34
2	Current assets	
	Inventories	16188.77
	Current financial asset	
	Current investments	0
	Trade receivables, current	25167.42
	Cash and cash equivalents	260.38
	Bank balance other than cash and cash equivalents	184.7
	Loans, current	0
	Other current financial assets	3343.18
	Total current financial assets	28955.68
	Current tax assets (net)	
	Other current assets	3395.85
	Total current assets	48540.3
3	Non-current assets classified as held for sale	7550.98
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	83304.62
	Total current assets	48540.3
3	Non-current assets classified as held for sale	7550.98
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	83304.62
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	1579.16

	Other equity	45037.26
	Total equity attributable to owners of parent	46616.42
	Non controlling interest	
	Total equity	46616.42
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	6466.51
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	25.4
	Total non-current financial liabilities	6491.91
	Provisions, non-current	498.1
	Deferred tax liabilities (net)	
	Deferred government grants, Non-current	
	Other non-current liabilities	
	Total non-current liabilities	6990.01
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	15795.91
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	844.01
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	8703.3
	Total Trade payable	9547.31
	Other current financial liabilities	1049.66
	Total current financial liabilities	26392.88
	Other current liabilities	707.41
	Provisions, current	126.33
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	27226.62
3	Liabilities directly associated with assets in disposal group classified as held for sale	2471.57
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	36688.2
	Total equity and liabilities	83304.62
	Disclosure of notes on assets and liabilities	Textual Information(1)

Other Comprehensive Income			
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Items that will not be reclassified to profit or loss	461.27	183.09
	Total Amount of items that will not be reclassified to profit and loss	461.27	183.09
2	Income tax relating to items that will not be reclassified to profit or loss	116.10	46.08
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	345.17	137.01

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	4600.77
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	2790.44
	Adjustments for decrease (increase) in inventories	-1784.95
	Adjustments for decrease (increase) in trade receivables, current	-6832.8
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	1102.04
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	-50.99
	Adjustments for increase (decrease) in trade payables, current	0
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	0
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	2791.78
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	1294.46
	Adjustments for unrealised foreign exchange losses gains	-385.62
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-401.11
	Other adjustments for non-cash items	-503.38
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-1980.13
	Net cash flows from (used in) operations	2620.64
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	458.59
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	2162.05
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0

	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	11
	Purchase of property, plant and equipment	1153.85
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	50.59
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-389.25
	Net cash flows from (used in) investing activities	-1481.51
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	14969.75
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	4500
	Repayments of borrowings	17028.05
	Payments of lease liabilities	12.91
	Dividends paid	275.98
	Interest paid	2790.44
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	-637.63
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	42.91
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	42.91

	Cash and cash equivalents cash flow statement at beginning of period	217.47
	Cash and cash equivalents cash flow statement at end of period	260.38

Format for Disclosure of Related Party Transactions (applicable only for half-y												
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							
1	Bajaj Healthcare Limited	AABCB0103B	Mr. Sajankumar Bajaj	ADOPB0559Q	Chairman & Managing Director	Remuneration			NA			197.48
2	Bajaj Healthcare Limited	AABCB0103B	Mr. Anil Jain	ADYPJ7000Q	Managing Director	Remuneration			NA			137.48
3	Bajaj Healthcare Limited	AABCB0103B	Mr. Dhanajay Hatle	AADPH3173N	Whole-Time Director	Remuneration			NA			18.24
4	Bajaj Healthcare Limited	AABCB0103B	Ms. Namrata Bajaj	AJPPB0498M	Whole-Time Director	Remuneration			NA			8.62
5	Bajaj Healthcare Limited	AABCB0103B	Mr. Pakshal Jain	BFEPJ4050H	Whole-Time Director	Remuneration			NA			11.64
6	Bajaj Healthcare Limited	AABCB0103B	Mr. Hemant Karnik	AFQPK3158J	Non-Executive Independent Director	Any other transaction	Sitting Fees for Board & Committee Meetings		NA			0.93
7	Bajaj Healthcare Limited	AABCB0103B	Mr. Ram Banarse	ABGPB4200Q	Non-Executive Independent Director	Any other transaction	Sitting Fees for Board & Committee Meetings		NA			0.88
8	Bajaj Healthcare Limited	AABCB0103B	Mr. Sandeep Shah	AVZPS7893K	Non-Executive Independent Director	Any other transaction	Sitting Fees for Board & Committee Meetings		NA			0.35
9	Bajaj Healthcare Limited	AABCB0103B	Mr. Yaqoob Ali	AAQPA4323E	Non-Executive Independent Director	Any other transaction	Sitting Fees for Board & Committee Meetings		NA			0
10	Bajaj Healthcare Limited	AABCB0103B	Mrs. Kejal Shah	BESPM2634H	Non-Executive Independent Director	Any other transaction	Sitting Fees for Board & Committee Meetings		NA			0.15
11	Bajaj Healthcare Limited	AABCB0103B	Mrs. Nihita Bajaj Kumar	BFJPB2052N	Daughter of Mr. Sajankumar Bajaj, Chairman & Managing Director & Sister of Ms. Namrata Bajaj, Whole-Time Director	Any other transaction	Legal & Professional Fees	15	Approved by the Audit Committee			6
12	Bajaj Healthcare Limited	AABCB0103B	Ms. Khushi Jain	CJAPJ8785Q	Daughter of Mr. Anil Jain, Managing Director & Sister of Mr. Pakshal	Any other transaction	Legal & Professional Fees	12	Approved by the Audit Committee			3

					Jain, Whole- Time Director							
13	Bajaj Healthcare Limited	AABCB0103B	Mrs. Dhanshree D Hatle	ACGPH0797K	Wife of Mr. Dhananjay Hatle, Whole- Time Director	Any other transaction	Legal & Professional Fees	5	Approved by the Audit Committee			2.31
14	Bajaj Healthcare Limited	AABCB0103B	Mrs. Harshavi Pakshal Jain	BENPJ6676R	Wife of Mr. Pakshal Jain, Whole- Time Director & Daughter- in-law of Mr. Anil Jain, Managing Director	Remuneration			NA			8.66
15	Bajaj Healthcare Limited	AABCB0103B	Mr. Sajankumar Bajaj	ADOPB0559Q	Chairman & Managing Director	Loan		5000	Approved by the Audit Committee			125
16	Bajaj Healthcare Limited	AABCB0103B	Ms. Apurva Bandivadekar	CUZPB7534F	Company Secretary (Resigned as on 31.01.2025)	Remuneration			NA			1.17
17	Bajaj Healthcare Limited	AABCB0103B	Mr. Dayashankar Patel	AAJPP0767E	Chief Financial Officer (Resigned as on 15.04.2025)	Remuneration			NA			11.45
18	Bajaj Healthcare Limited	AABCB0103B	Ms. Monica Tanwar	ANVPT3297J	Company Secretary (Appointed as on 11.02.2025)	Remuneration			NA			1.19
Total value of transaction during the reporting period												534.55

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Walker Chandiok Co & LLP	Yes	31-05-2025

